Madopar is contraindicated in: patients with known hypersensitivity to levodopa or benserazide or any of the excipients.
Patients receiving non-selective monoamine oxidase (MAO) inhibitors due to the risk of hypertensive crisis (see General under Precautions). However, selective MAO-B inhibitors, such as selegiline and rasagiline or selective MAO-A inhibitors, such as moclobemide, are not contraindicated. Combination of MAO-A and MAO-B inhibitors is equivalent to non-selective MAO inhibition, and hence this combination should not be given concomitantly with Madopar (see Interactions).
Patients with decompensated endocrine, renal or hepatic function, cardiac disorders, psychiatric diseases with a psychotic component or closed angle glaucoma.
Patients less than 25 years old (skeletal development must be complete).
Pregnant women or to women of childbearing potential in the absence of adequate contraception (see Use in Pregnancy & Lactation). If pregnancy occurs in a woman taking Madopar, the drug must be discontinued (as advised by the prescribing physician).